The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease• Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working• MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies

Latest in the News

All News →
LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease
 GASTROINTESTINAL

LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease

Locus Biosciences’ CTO explains why an engineered phage cocktail aimed at adherent-invasive E. coli could address a suspected driver of Crohn’s disease.

BY Nick Conley · NOV 11, 2026 · 11 MIN READ
Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working
FINANCE

Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working

NOV 11, 2026
MIT engineers create nanoparticles for delivering personalized cancer vaccines
ONCOLOGY

MIT engineers create nanoparticles for delivering personalized cancer vaccines

NOV 9, 2026
MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines
CLINICAL & MANUFACTURING

MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines

NOV 5, 2026
Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics
GASTROINTESTINAL

Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics

NOV 3, 2026
Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease
REGULATORY & POLICY

Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease

OCT 30, 2026
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
 Editor's Choice

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

Prokarium’s live bacterial immunotherapy ZH9 aims to redefine the non-muscle invasive bladder cancer treatment paradigm, building upon the precedence of BCG with a product designed for real-world urology practice.

BY Nick Glanville, Livija Deban and Dara Henry · SEP 28, 2026 · 9 MIN READ
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026